The Chronic Kidney Disease Solution™ by Shelly Manning It is an eBook that includes the most popular methods to care and manage kidney diseases by following the information provided in it. This easily readable eBook covers up various important topics like what is chronic kidney disease, how it is caused, how it can be diagnosed, tissue damages caused by chronic inflammation, how your condition is affected by gut biome, choices for powerful lifestyle and chronic kidney disease with natural tools etc.
How does incremental peritoneal dialysis preserve residual function, what observational/RCT data show, and how does this compare with full-dose PD from start?
Incremental peritoneal dialysis (IPD) preserves residual kidney function (RKF) primarily by minimizing exposure to bioincompatible dialysis solutions and maintaining better physiological fluid balance compared to starting with full-dose PD. Observational data largely support this, showing a slower decline in RKF for patients on IPD. However, data from randomized controlled trials (RCTs) are scarce and have not conclusively confirmed this benefit, showing similar rates of RKF decline between IPD and full-dose groups.
The approach is less burdensome for patients initially and is associated with a better quality of life. It requires close monitoring to increase the dialysis dose as RKF declines to prevent under-dialysis
Preserving the Priceless: A Deep Dive into Incremental Peritoneal Dialysis and Residual Kidney Function
Incremental Peritoneal Dialysis (IPD) represents a patient-centered, physiology-respecting approach to initiating dialysis. Instead of starting with a standard “full-dose” regimen, IPD tailors the initial dialysis prescription to supplement the patient’s existing, albeit declining, residual kidney function (RKF). The goal is elegantly simple yet profoundly impactful: to keep the native kidneys contributing to waste and fluid clearance for as long as possible. 🩺 This strategy is built on the growing recognition that RKF is not just a number but a powerful predictor of better patient outcomes, including improved survival and quality of life.
How Incremental PD Preserves Residual Kidney Function: The Core Mechanisms
The preservation of RKF under IPD is not attributed to a single factor but rather a synergy of several mechanisms that reduce the stress on both the remaining nephrons and the peritoneal membrane.
1. Reduced Exposure to Bioincompatible Solutions & Glucose Load 🧪
Standard peritoneal dialysis solutions, particularly those using glucose as an osmotic agent, are inherently bioincompatible. The high glucose concentration, low pH, and presence of glucose degradation products (GDPs) from heat sterilization can be toxic to both the peritoneal membrane and potentially the rest of the body.
- Peritoneal Membrane Health: Chronic exposure to these solutions induces inflammation, fibrosis, and angiogenesis (formation of new blood vessels) in the peritoneal membrane. This long-term damage can lead to ultrafiltration failure, where the membrane loses its ability to remove excess fluid effectively. IPD, by using fewer exchanges and a lower volume of dialysate, directly reduces the cumulative exposure to these toxic elements, helping to preserve the membrane’s integrity for longer.
- Systemic and Renal Impact: A significant amount of glucose from the dialysate is absorbed into the bloodstream. This chronic glucose load can contribute to systemic inflammation and oxidative stress, which are known drivers of cardiovascular disease and may accelerate the decline of RKF. By minimizing this glucose absorption, IPD lessens this systemic burden.
2. Avoidance of Dehydration and Intradialytic Hypotension 💧
One of the most critical aspects of RKF preservation is maintaining stable renal perfusion (blood flow to the kidneys).
- The Danger of Over-Ultrafiltration: A full-dose PD regimen in a patient who still produces a significant amount of urine can easily lead to excessive fluid removal (over-ultrafiltration). This can cause episodes of dehydration and hypotension (low blood pressure).
- Renal Ischemia: Hypotensive episodes reduce blood flow to the kidneys, leading to ischemic injury in the remaining functional nephrons. Repeated ischemic insults are a well-established cause of accelerated RKF loss.
- Gentler Fluid Management: IPD leverages the patient’s own ability to excrete water. The dialysis prescription is designed to supplement, not aggressively replace, this function. This leads to a more stable and physiological fluid status, protecting the kidneys from the damaging effects of hemodynamic instability.
3. Mitigating Systemic Inflammation 🔥
Chronic kidney disease is a state of chronic systemic inflammation. The initiation of dialysis can itself be an inflammatory trigger.
- Dialysis as an Inflammatory Stimulus: The presence of a catheter, the infusion of large volumes of fluid, and the bioincompatibility of the solutions can all exacerbate the underlying inflammatory state.
- A Softer Start: IPD provides a “gentler” introduction to dialysis. By starting with a lower dose, it is theorized that the incremental approach provokes a less intense inflammatory response compared to the abrupt start of a full-dose regimen. Reducing inflammation is beneficial for cardiovascular health and is thought to slow the progression of remaining kidney disease.
The Evidence: Observational Studies vs. Randomized Controlled Trials
The clinical evidence examining IPD’s effect on RKF presents a classic case of “where theory and practice meet.” While a large body of observational data supports the benefits of IPD, the gold-standard evidence from RCTs remains limited and less conclusive.
Observational Studies: A Chorus of Support
Numerous observational studies from around the world have reported positive outcomes for patients starting on IPD.
- Slower RKF Decline: A consistent finding across many studies is a slower rate of decline in glomerular filtration rate (GFR) and urine volume in patients on IPD compared to those starting on conventional full-dose PD. For example, a study by Viglino et al. in Italy found that the rate of RKF loss was significantly slower in the IPD group.
- Comparable or Better Survival: These studies generally show that starting with IPD does not compromise patient survival. In fact, some suggest a trend towards better survival, likely mediated by the preservation of RKF.
- Safety and Efficacy: Research has shown that IPD is a safe approach, with no increase in major complications like peritonitis. Technique survival (the length of time a patient can remain on PD) is often reported to be equivalent or superior to full-dose PD.
- Caveat: The major limitation of these studies is selection bias. Nephrologists may be more likely to offer IPD to healthier, more motivated patients who have better RKF to begin with. Therefore, the better outcomes observed could be due to the patient population rather than the treatment modality itself.
Randomized Controlled Trials (RCTs): A More Sobering View
RCTs are designed to eliminate selection bias, providing a higher level of evidence. To date, high-quality, large-scale RCTs specifically designed to test the effect of IPD on RKF decline are lacking.
- The balANZ Trial (Post-Hoc Analysis): This large trial originally compared outcomes between PD and hemodialysis. A subsequent post-hoc (after the fact) analysis examined patients who were effectively on an incremental regimen. This analysis did not find a significant difference in the rate of RKF decline between patients on a lower-intensity regimen and those on a standard full dose over 24 months.
- Ongoing and Pilot RCTs: Several smaller pilot RCTs have been conducted. While they have established that an incremental start is feasible and safe, they have been underpowered to detect a statistically significant difference in the rate of RKF decline. For instance, a pilot study by Lo et al. found no difference in RKF decline at 12 months, though the IPD group reported better quality of life.
The lack of definitive evidence from RCTs means the nephrology community cannot yet claim with certainty that IPD is superior for RKF preservation. However, it does show that starting with a lower dose is at least not harmful and offers other tangible benefits.
Head-to-Head Comparison: Incremental PD vs. Full-Dose PD from the Start
Frequently Asked Questions (FAQ)
1. Does starting IPD mean you are starting dialysis “too early”? No. The decision to initiate dialysis is based on clinical indications, such as uremic symptoms (nausea, fatigue), fluid overload, or biochemical abnormalities (like hyperkalemia) that cannot be managed conservatively. IPD is a method of starting dialysis once the decision to begin has already been made. It’s about how you start, not when you start.
2. How do you know when to increase the dialysis dose in IPD? The dose is increased based on three factors:
- Residual Kidney Function: Regular measurement of the patient’s 24-hour urine clearance (renal Kt/V) is the most objective measure. As it declines, the dialysis dose is increased to maintain a target total clearance.
- Clinical Symptoms: If a patient develops symptoms of uremia, such as loss of appetite, fatigue, or fluid retention, the dose is increased.
- Biochemical Parameters: Worsening lab values, like rising creatinine, urea, or potassium, also signal the need for a higher dose.
3. Is IPD more complicated for the patient? Initially, the daily routine of IPD is less complicated and time-consuming than full-dose PD. However, the overall management requires a stronger partnership between the patient and the healthcare team. The patient must be committed to performing regular 24-hour urine collections, which can be cumbersome. The complexity lies in the monitoring, not the daily procedure itself.
4. Can any PD patient start with an incremental approach? IPD is best suited for patients who have significant RKF when they begin dialysis. The ideal candidate typically has a urine output of more than 500-750 mL per day. It is not appropriate for patients who are anuric (produce no urine) or who present late with severe uremic symptoms, as they require immediate, full-dose renal replacement therapy.
5. What is the most significant benefit of preserving residual kidney function? The single most important benefit is improved survival. Numerous large-scale studies have consistently shown that for every 250 mL of daily urine output a patient on dialysis maintains, their mortality risk decreases significantly. Beyond survival, RKF is linked to better control of anemia and phosphorus, improved nutritional status, higher quality of life, and better blood pressure control. It is arguably the most valuable asset a new dialysis patient has. ✨
I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. Learn more |